Wei Yue, Ph.D.

---

Summary

My research program focuses on studying novel mechanisms involved in regulation of OATP1B1 and OATP1B3 transport function. The long-term goal of my laboratory is to establish a mechanistic model to predict OATP-mediated drug-drug interactions, toxicities and inter-individual variability in drug response. Multi-disciplinary approaches are utilized including: 1) Sandwich-cultured primary human hepatocytes model; 2) Physiologically based pharmacokinetic (PBPK) modeling approach to assess clinically relevant DDIs; 3) Pharmacogenomics studies of drug transport proteins; 4) Post-translational regulation of OATP transporters; 5) Confocal microscopy to study trafficking of the transport proteins.

Academic Awards

---

Publications & Presentations

21. Alam K, Farasyn T, Ding K, Yue W. Characterization of liver- and cancer-type-organic anion transporting polypeptide (OATP) 1B3 messenger RNA expression in normal and cancerous human tissues. Drug Metabolism Letters. 2018

22. Alam K, Farasyn T, Crowe A, Ding K, Yue W. Treatment with Proteasome Inhibitor Bortezomib Decreases Organic Anion Transporting Polypeptide (OATP) 1B3-Mediated Transport in a Substrate-Dependent Manner. Public Library of Science ONE. 2017; 12 : e0186924

23. Pahwa S, Alam K, Crowe A, Farasyn T, Sibylle N, Hatley O, Ding K, Yue W. Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport. Journal of Pharmaceutical Sciences. 2017; 106 : 2123

24. Alam K, Pahwa S, Wang X, Zhang P, Ding K, Abuznait A, Li L, Yue W. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. Molecular Pharmaceutics. 2016; 13 : 839–851

25. Farasyn T. Rapid down-regulation of organic anion transporting polypeptide (OATP) 1B3 transport function by phosphorylation modulators in sandwich-cultured hepatocytes: A novel mechanism of OATP1B3 inhibition. Drug Metabolism Reviews. 2015; 47(S1) : 259

Grants

1. Equipment supplement award-Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors . NIH. Start Date: 2024. End Date: 2026.

2. Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors . NIH. Start Date: 2022. End Date: 2026.

3. Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors . Misc Non-Federal. Start Date: 2022. End Date: 2022.

4. Lysine Acetylation: A novel mechanism governing organic anion transporting polypeptides OATP1B1- and OATP1B3-mediated transport. Misc Non-Federal. Start Date: 2021. End Date: 2022.

5. Elucidating novel mechanism underlying OATP1B1/1B3-mediated drug-drug interactions . Non-federal. Start Date: 2019. End Date: 2020.

Awards and Honors

1. OUHSC. Regents’ Award for Superior Teaching. Date: 2024.


2. ASPET. ASPET IDEA Faculty Scholars. Date: 2024.


3. WiSDMH at OUHSC. Recognition of OUHSC Women in Science Dentistry Medicine and Health. Date: 2022.


4. OUHSC. Member of Educators for Excellence of OUHSC. Date: 2022.


5. OUHSC. Provost’s Teaching Award-Early Career Faculty . Date: 2021.

Education

1. Degree: Postdoctoral training. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Date: 2008.


2. Degree: Postdoctoral Training. Lineberger Comprehensive Cancer Center, Univeristy of North Carolina at Chapel Hill. Date: 2007.


3. Degree: Ph D. Peking Union Medical College and Shandong University, China. Date: 2001.


4. Degree: MS. Shandong University, China. Date: 1998.


5. Degree: BS. Shandong Agricultural University, China. Date: 1995.

Administrative Assignments

no results